OM:SHOT
OM:SHOTHospitality

Should Scandic’s New Stuttgart and Floro Hotels Shape Action From Scandic Hotels Group (OM:SHOT) Investors?

Scandic Hotels Group has recently expanded its footprint by opening Scandic Stuttgart Europaviertel, its eighth hotel in Germany with 174 rooms, and Scandic Victoria Floro, its first hotel in the Norwegian coastal town of Floro with 97 rooms, both supporting meetings and event demand. These openings highlight Scandic’s push toward its 2030 goal of adding about 10,000 new rooms, using a mix of German growth and Nordic franchise partnerships to broaden its network and brand reach. Next, we’ll...
OM:SOBI
OM:SOBIBiotechs

Is Swedish Orphan Biovitrum (OM:SOBI) Still Undervalued After Its Recent Share Price Pullback?

Swedish Orphan Biovitrum (OM:SOBI) has quietly delivered strong multi year gains, and with the share price easing about 3% over the past month, investors are starting to reassess whether the current pullback offers value. See our latest analysis for Swedish Orphan Biovitrum. At around SEK 329.6, the recent 7 day and 30 day share price pullback sits against a still solid 90 day share price return of 18.1% and a five year total shareholder return above 100%. This suggests longer term momentum...
OM:HUSQ B
OM:HUSQ BMachinery

How Husqvarna’s 2030 Cost‑Out and CO₂ Targets At Husqvarna (OM:HUSQ B) Has Changed Its Investment Story

Earlier this month, Husqvarna Group outlined its priorities through 2030, targeting 3–5% annual organic sales growth and a 60% cut in CO₂ emissions, backed by a cost-out program aiming for SEK 4.00 billion in yearly savings. Beyond efficiency, the plan signals a deeper shift toward combining financial discipline with sustainability metrics as equal yardsticks of success. We’ll now explore how this long-term cost-out program reshapes Husqvarna’s investment narrative and its path toward...
OM:PDX
OM:PDXEntertainment

How Investors Are Reacting To Paradox Interactive (OM:PDX) Launching Victoria 3: Iberian Twilight DLC

On 11 December 2025, Paradox Interactive released Victoria 3: Iberian Twilight, a US$9.99 immersion pack adding Spain- and Portugal-focused historical content, new mechanics, and visual upgrades to its grand strategy title. This new downloadable content deepens engagement in one of Paradox’s key live-service franchises, reinforcing its model of monetizing long-lived game communities. We’ll now assess how this fresh Iberian-themed Victoria 3 content drop feeds into Paradox Interactive’s...
OM:HM B
OM:HM BSpecialty Retail

Is H&M (OM:HM B) Overvalued After Its Recent Share Price Rebound? A Closer Look at the Valuation

H & M Hennes & Mauritz (OM:HM B) has been quietly rewarding patient shareholders, with the stock gaining about 22% over the past 3 months and roughly 20% year to date. See our latest analysis for H & M Hennes & Mauritz. At around SEK 178.65 per share, the 90 day share price return of about 22% and a three year total shareholder return above 80% suggest momentum is clearly building again as investors warm to H & M Hennes & Mauritz’s recovery story. If H & M’s rebound has you rethinking retail,...
OM:SAAB B
OM:SAAB BAerospace & Defense

Assessing Saab (OM:SAAB B) Valuation After Breakthrough Autonomous Aircraft Fuselage Milestone with Divergent Technologies

Saab (OM:SAAB B) just hit an interesting milestone with Divergent Technologies, delivering initial autonomous aircraft fuselages built using fully digital, additive manufacturing. For investors, this is less about near term revenue and more about long term capability. See our latest analysis for Saab. That milestone with Divergent lands after a busy spell for Saab, with fresh Spanish Army training contracts and another Lithuanian MSHORAD order. It comes on top of a powerful year to date share...
OM:BONEX
OM:BONEXBiotechs

Shifting CERAMENT V To FDA De Novo Review Might Change The Case For Investing In Bonesupport Holding (OM:BONEX)

BONESUPPORT has already shifted its U.S. regulatory route for CERAMENT V for bone infection from a 510(k) submission to the FDA’s De Novo pathway, extending the formal review period from 90 to 150 days while transferring substantial existing clinical and pharmacological documentation. This move suggests CERAMENT V could, if cleared, create a new product category in the U.S., echoing how CERAMENT G previously established a distinct regulatory class and potentially underscoring the uniqueness...